The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

about

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

Item

http://www.wikidata.org/entity/Q55222782

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

@en

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

@nl

type

Item

label

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

@en

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

@nl

prefLabel

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

@en

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

@nl

P1476

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.

@en

P2093

Catherine Johanet

http://www.w3.org/2001/XMLSchema#string

Hanna Debiec

http://www.w3.org/2001/XMLSchema#string

Karine Dahan

http://www.w3.org/2001/XMLSchema#string

Pierre Ronco

http://www.w3.org/2001/XMLSchema#string

Valentine Gillion

http://www.w3.org/2001/XMLSchema#string

P2860

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy

Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy

PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.

Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy

A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy

P304

498-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.EKIR.2017.10.013

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29725656

http://www.w3.org/2001/XMLSchema#string

P932

5932125

http://www.w3.org/2001/XMLSchema#string